Company Overview of Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., an early stage biotechnology company, applies immunotherapy to auto-immune diseases. The company focuses on developing complement immunotherapies for diseases of the lungs, such as asthma and chronic obstructive pulmonary disease; diseases of the retina, including age-related macular degeneration; and rare hematological diseases, such as paroxysmal nocturnal hemoglobinuria. Its drug compound, APL-2, is used in patients suffering from age-related macular degeneration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.
6400 Westwind Way
Crestwood, KY 40014
Founded in 2009
Key Executives for Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|Xsira Pharmaceuticals, Inc.||United States|
|Maxygen, Inc.||United States|
|Microbes BioSciences, Inc.||United States|
|Schepens Eye Research Institute Inc.||United States|
|Osprey Biomedical Corp.||United States|
Recent Private Companies Transactions
December 5, 2014
December 2, 2014
November 20, 2014
|Potentia Pharmaceuticals, Inc.|
To contact Apellis Pharmaceuticals, Inc., please visit www.apellis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.